LLY – Eli Lilly and Company
Eli Lilly and CompanyLLY
$1,038.27Name : Eli Lilly and Company
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $930,764,161,024.00
EPSttm : 22.95
Eli Lilly and Company
$1,038.27
2.27%$23.06Float Short %
0.82
Margin Of Safety %
-6
Put/Call OI Ratio
1.07
EPS Next Q Diff
EPS Last/This Y
EPS This/Next Y
7.48
Price
1038.12
Target Price
1236.73
Analyst Recom
1.53
Performance Q
5.02
Relative Volume
1.06
Beta
0.4
Ticker: LLY
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-01-14 | LLY | 1073.8 | 0.96 | 0.88 | 386324 |
| 2026-01-15 | LLY | 1032.07 | 0.96 | 0.96 | 390377 |
| 2026-01-16 | LLY | 1039.43 | 0.95 | 0.76 | 404145 |
| 2026-01-20 | LLY | 1041.29 | 1.01 | 1.00 | 284995 |
| 2026-01-21 | LLY | 1079.49 | 1.02 | 0.86 | 293067 |
| 2026-01-22 | LLY | 1087.33 | 1.03 | 0.84 | 302777 |
| 2026-01-23 | LLY | 1065.28 | 1.03 | 1.04 | 313585 |
| 2026-01-26 | LLY | 1062.86 | 1.03 | 1.44 | 291318 |
| 2026-01-27 | LLY | 1038 | 1.04 | 1.01 | 299092 |
| 2026-01-28 | LLY | 1023.51 | 1.05 | 0.95 | 308535 |
| 2026-01-29 | LLY | 1023.74 | 1.04 | 0.81 | 319692 |
| 2026-01-30 | LLY | 1037.91 | 1.04 | 0.71 | 322679 |
| 2026-02-02 | LLY | 1043.58 | 1.06 | 1.01 | 296369 |
| 2026-02-04 | LLY | 1106.23 | 1.07 | 1.04 | 319938 |
| 2026-02-05 | LLY | 1018.67 | 1.06 | 0.82 | 328113 |
| 2026-02-06 | LLY | 1058.18 | 1.07 | 0.75 | 336799 |
| 2026-02-09 | LLY | 1044.76 | 1.06 | 0.67 | 310644 |
| 2026-02-10 | LLY | 1025 | 1.06 | 0.78 | 322349 |
| 2026-02-11 | LLY | 1014.84 | 1.06 | 0.72 | 330459 |
| 2026-02-12 | LLY | 1038.95 | 1.07 | 0.24 | 334616 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-01-14 | LLY | 1073.32 | 35.8 | 12298.9 | 23.66 |
| 2026-01-15 | LLY | 1030.39 | 35.8 | 11038.5 | 23.66 |
| 2026-01-16 | LLY | 1038.40 | 35.8 | 12605.3 | 23.66 |
| 2026-01-20 | LLY | 1041.00 | 35.4 | 12510.0 | 23.66 |
| 2026-01-21 | LLY | 1078.52 | 35.4 | 13660.9 | 23.66 |
| 2026-01-22 | LLY | 1087.38 | 35.4 | 12708.1 | 23.66 |
| 2026-01-23 | LLY | 1064.29 | 35.4 | 11687.3 | 23.66 |
| 2026-01-26 | LLY | 1062.75 | 32.7 | 12373.2 | 23.66 |
| 2026-01-27 | LLY | 1039.09 | 31.3 | 11920.5 | 23.66 |
| 2026-01-28 | LLY | 1023.80 | 31.3 | 12170.2 | 23.66 |
| 2026-01-29 | LLY | 1024.14 | 31.3 | 12709.0 | 23.66 |
| 2026-01-30 | LLY | 1037.15 | 30.6 | 13140.2 | 23.66 |
| 2026-02-02 | LLY | 1044.13 | 30.6 | 12932.1 | 23.66 |
| 2026-02-03 | LLY | 1004.00 | 30.6 | 11356.7 | 23.66 |
| 2026-02-04 | LLY | 1107.50 | 30.6 | 16309.0 | 23.66 |
| 2026-02-05 | LLY | 1020.88 | 128.9 | 9975.0 | 33.30 |
| 2026-02-06 | LLY | 1057.89 | 128.9 | 13965.6 | 33.30 |
| 2026-02-09 | LLY | 1044.67 | 125.8 | 13121.0 | 34.15 |
| 2026-02-10 | LLY | 1025.69 | 117.4 | 12928.2 | 34.12 |
| 2026-02-12 | LLY | 1038.12 | 117.6 | 14382.9 | 34.28 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-01-14 | LLY | -4.19 | -1.11 | 0.82 |
| 2026-01-15 | LLY | -4.20 | -1.11 | 0.82 |
| 2026-01-16 | LLY | -4.20 | -1.11 | 0.82 |
| 2026-01-20 | LLY | -4.20 | -1.13 | 0.82 |
| 2026-01-21 | LLY | -4.20 | -1.13 | 0.82 |
| 2026-01-22 | LLY | -4.20 | -1.13 | 0.82 |
| 2026-01-23 | LLY | -4.20 | -1.13 | 0.82 |
| 2026-01-26 | LLY | -3.93 | -1.15 | 0.82 |
| 2026-01-27 | LLY | -3.93 | -1.15 | 0.82 |
| 2026-01-28 | LLY | -3.93 | -1.15 | 0.90 |
| 2026-01-29 | LLY | -3.93 | -1.15 | 0.90 |
| 2026-01-30 | LLY | -3.93 | -1.15 | 0.90 |
| 2026-02-02 | LLY | -3.93 | -1.17 | 0.90 |
| 2026-02-03 | LLY | -3.93 | -1.17 | 0.90 |
| 2026-02-04 | LLY | -3.93 | -1.17 | 0.90 |
| 2026-02-05 | LLY | -3.93 | -1.17 | 0.90 |
| 2026-02-06 | LLY | -3.93 | -1.17 | 0.90 |
| 2026-02-09 | LLY | -3.93 | -0.71 | 0.90 |
| 2026-02-10 | LLY | -3.93 | -0.71 | 0.90 |
| 2026-02-11 | LLY | -3.93 | -0.71 | 0.82 |
| 2026-02-12 | LLY | -3.93 | -0.71 | 0.82 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
7.27
Avg. EPS Est. Next Quarter
8.05
Insider Transactions
-3.93
Institutional Transactions
-0.71
Beta
0.4
Average Sales Estimate Current Quarter
17335
Average Sales Estimate Next Quarter
19411
Fair Value
977.9
Quality Score
97
Growth Score
100
Sentiment Score
62
Actual DrawDown %
8.5
Max Drawdown 5-Year %
-34.5
Target Price
1236.73
P/E
45.23
Forward P/E
25.12
PEG
0.95
P/S
15.06
P/B
41.27
P/Free Cash Flow
105.86
EPS
22.96
Average EPS Est. Cur. Y
34.28
EPS Next Y. (Est.)
41.76
Target Price Estimates Raised
1
Target Price Estimates Lowered
Profit Margin
31.66
Relative Volume
1.06
Return on Equity vs Sector %
49.5
Return on Equity vs Industry %
41.3
EPS 1 7Days Diff
0.9
EPS 1 30Days Diff
1.3
EBIT Estimation
14382.9
Eli Lilly and CompanySector: Healthcare
Industry: Drug Manufacturers - General
Employees:
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd; Strategic Collaboration with Eli Lilly to advance development of its myeloid engager platform for autoimmune disease, as well as Strategic partnership with NVIDIA Corporation. The company also has a research collaboration agreement with Insilico Medicine for the development of advance therapies; and Nimbus Therapeutics, LLC for the development of novel oral treatment for obesity and other metabolic diseases. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
stock quote shares LLY – Eli Lilly and Company Stock Price stock today
news today LLY – Eli Lilly and Company stock forecast ,stock prediction 2023 2024 2025
marketwatch LLY – Eli Lilly and Company yahoo finance google finance
stock history LLY – Eli Lilly and Company invest stock market
stock prices LLY premarket after hours
ticker LLY fair value insiders trading